Today Smith & Nephew announced that Namal Nawana will step down from his position of CEO and Board member on October 31. Effective November 1, Roland Diggelmann, most recently the CEO of Roche Diagnostics, will assume the role of CEO of Smith & Nephew. Nawana will stay at the company until December 31 to help with the transition.
Nawana’s exit is reportedly over salary, according to various media reports, including Reuters. According to Reuters, Nawana only joined Smith & Nephew in 2018, receiving $2.88 million that year, while the previous CEO, Olivier Bohuon received $5.12 million the previous year.
“Namal has been instrumental in delivering on a critical phase of Smith+Nephew’s development, accelerating revenue growth across franchises and geographies as well as improving profitability,” stated a Smith & Nephew press release. “The new CEO and senior leadership team will now build on these strong foundations to further drive commercial execution and deliver on the Company’s strategic ambitions.”
Related Articles
-
Leslie Trigg, CEO of Outset Medical, is the new Chair of The Medical Device Manufacturers Association (MDMA) Board of Directors.
-
“I am honored to welcome Thierry Bernard as the new chair of the AdvaMedDx Board. With his decades of experience, Thierry brings a clear vision of the work we can accomplish, and I look forward to working with him.”
-
It is more important than ever for medical manufacturers to prepare for business interruption due to unexpected damage or natural disasters. From building a recovery team to securing proper insurance, there are many steps device manufacturers can take to recover…
-
Nondisclosure agreements (NDAs) can help protect trade secrets and build a framework for better cooperation and understanding between parties. Following are some key areas to consider when creating an NDA.
